]>
IRCT138902033777N1 IRCT 2003-10-10 Drug Applied Research Center-Tabriz University of Medical Sciences The effect of zinc supplementation in chronic hemodialysis patients Improvement of oxidative stress injuries following the supplementation of zinc in chronic hemodialysis patients 2003-10-10 anticipated 73 Complete https://irct.ir/trial/3895 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Crossover, Purpose: Basic scienece. 2-3 patients with hemodialsis. Intervention 1: cornstarch, 2 capsules per day for 2 months. Intervention 2: zinc sulfates pentahydrate, two 220 mg capsules per day for 2 months.
public Mohammad Mazani
Faculty of medicine, Ardabil University of Medical sciences,
Ardabil Iran (Islamic Republic of) 56198-53142 +98 45 1551 2788 m.mazani@www.arums.ac.ir Ardabil University of Medical sciences - faculty of medicine scientific Mohammad Mazani
Faculty of medicine, Ardabil University of Medical sciences, Ardabil
Ardabil Iran (Islamic Republic of) 56198-53142 +98 45 1551 2788 m.mazani@www.arums.ac.ir Faculty of medicine, Ardabil University of Medical sciences Iran (Islamic Republic of) Inclusion criteria: Hemodialysis more than 6 month, Age more than 20 year, referring to Tabriz Sina Hospital for hemodialysis Exclusion criteria: presence of gastrointestinal disorders, smoking, kidney transplantation candidates, lactation, pregnancy, consumption of glucocorticoids, antibiotics, penicilamine, estrogens or contraceptives (in females), hospitalization due to other reasons than chronic renal failure 20 years no limit Both N00, N01,N Acute nephritic syndrome, Rapidly progressive nephritic syndrome, Chronic nephritic syndrome, Nephrotic syndrome, Unspecified nephritic syndrome, Glomerular disorders in diseases classified elsewhere, Acute renal failure, Chronic renal failure, Unspecifie Placebo Treatment - Drugs cornstarch, 2 capsules per day for 2 months zinc sulfates pentahydrate, two 220 mg capsules per day for 2 months Serum level of zinc. Timepoint: Baseline and days 60, 120, and 180 after the intervention in each period. Method of measurement: as microgram per deciliter scale by atomic absorption spectrophotometry. Serum total antioxidant capacity. Timepoint: Baseline and days 60, 120, and 180 after the intervention in each period. Method of measurement: as mM scale by spectrophotometry. Red blood cell superoxide dismutase activity. Timepoint: Baseline and days 60, 120, and 180 after the intervention in each period. Method of measurement: as unit per gram of hemoglobin scale by spectrophotometry. Serum total glutathione. Timepoint: Baseline and days 60, 120, and 180 after the intervention in each period. Method of measurement: as mM scale by spectrophotometry. Malondialdehyde (MDA). Timepoint: Baseline and days 60, 120, and 180 after the intervention in each period. Method of measurement: as nmol/ml scale by spectrophotometry. Fasting serum glucose. Timepoint: Baseline and days 60, 120, and 180 after the intervention in each period. Method of measurement: as mg/dl scale by spectrophotometry. Serum total cholesterol. Timepoint: 4 time at 2 month interval at the 0th, 60th, 120th and 180th days of study (before and after intervention period, before and after placebo period). Method of measurement: as mg/dl scale by spectrophotometry. Serum triglyceride. Timepoint: Baseline and days 60, 120, and 180 after the intervention in each period. Method of measurement: as mg/dl scale by spectrophotometry. HDL cholesterol. Timepoint: Baseline and days 60, 120, and 180 after the intervention in each period. Method of measurement: as mg/dl scale by spectrophotometry. LDL cholesterol. Timepoint: Baseline and days 60, 120, and 180 after the intervention in each period. Method of measurement: as mg/dl scale by spectrophotometry. Serum total lipid. Timepoint: Baseline and days 60, 120, and 180 after the intervention in each period. Method of measurement: as mg/dl scale by spectrophotometry. Central and peripheral nerves evaluation. Timepoint: Baseline and days 60, 120, and 180 after the intervention in each period. Method of measurement: as m/s, ms and µv scales by electrodiagnostic test. Serum antiphospholipid. Timepoint: Baseline and days 60, 120, and 180 after the intervention in each period. Method of measurement: as u/ml by ELIZA. Cardiac ejection fraction. Timepoint: Baseline and days 60, 120, and 180 after the intervention in each period. Method of measurement: as % by echocardiography. Blood pressure. Timepoint: Baseline and days 60, 120, and 180 after the intervention in each period. Method of measurement: as mmHg by mercury manometer. Taste perception evaluation. Timepoint: Baseline and days 60, 120, and 180 after the intervention in each period. Method of measurement: scale of taste acuity by taste tesing (Fernstrom A et al. Nephrol 1996 :45(3):169-74). Pruritus evaluation. Timepoint: Baseline and days 60, 120, and 180 after the intervention in each period. Method of measurement: as pruritic score by pruritus questionnaire. Cell blood count (CBC) and diffraction. Timepoint: Baseline and days 60, 120, and 180 after the intervention in each period. Method of measurement: as number per microliter and % scale by Cell counter. Smell testing. Timepoint: Baseline and days 60, 120, and 180 after the intervention in each period. Method of measurement: smell test by pipe tobacco. Libido. Timepoint: Baseline and days 60, 120, and 180 after the intervention in each period. Method of measurement: by questionnaire. Drug Applied Research Center-Tabriz University of Medical Sciences Approved 2003-03-15 Drug Applied Research Center, Tabriz University of Medical Sciences Drug Applied Research Center, Medical Research and Development Complex, Daneshgah St., Tabriz Tabriz Iran (Islamic Republic of)